Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading PTN News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.31%72.131.0%$655.07m
AMGNAmgen Inc.
0.63%155.770.8%$509.15m
CELGCelgene Corporation
0.24%115.221.0%$465.18m
ARIAARIAD Pharmaceuticals, Inc.
0.23%23.7016.4%$416.43m
BIIBBiogen Inc.
0.21%283.611.0%$405.76m
ALXNAlexion Pharmaceuticals, Inc.
0.42%135.872.5%$385.05m
REGNRegeneron Pharmaceuticals, Inc.
-0.08%362.952.5%$365.07m
ILMNIllumina, Inc.
0.47%161.233.8%$225.12m
CLVSClovis Oncology, Inc.
0.64%56.6217.9%$166.73m
VRTXVertex Pharmaceuticals Incorporated
1.19%82.522.1%$152.50m
INCYIncyte Corporation
1.28%115.092.2%$149.42m
SRPTSarepta Therapeutics, Inc.
-0.42%35.9816.8%$110.90m
ACADACADIA Pharmaceuticals Inc.
3.06%32.3118.3%$110.16m
IONSIonis Pharmaceuticals, Inc.
1.12%47.148.9%$110.11m
TSROTESARO, Inc.
-1.32%149.2615.0%$109.40m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.